- •The largest ambispective study from a developing country on natalizumab and multiple sclerosis.
- •Natalizumab was found to be highly effective in Indian patients with MS.
- •Patients with RRMS and SPMS improved in relapse rate while EDSS improvement was observed only in the RRMS cohort.
- •The risk-benefit ratio appears highly favorable with no reports of PML.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.Ann. Neurol. 2016; 79: 950-958
- Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis.JAMA. 2019; 321 (Erratum in: JAMA. 2020 Apr 7;323(13):1318. PMID: 30644981; PMCID: PMC6439772): 175-187https://doi.org/10.1001/jama.2018.20588
- Tysabri Observational Program (TOP) Investigators. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).J. Neurol. Neurosurg. Psychiatry. 2020; 91: 660-668
- Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.Lancet Neurol. 2010; 9: 438-446https://doi.org/10.1016/S1474-4422(10)70028-4
- α4-integrin receptor desaturation and disease activity return after natalizumab cessation.Neurol. Neuroimmunol. Neuroinflamm. 2017; 4 (PMID: 28856176; PMCID: PMC5572051): e388https://doi.org/10.1212/NXI.0000000000000388
- Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.Patient Prefer. Adherence. 2017; 11 (PMID: 28670113; PMCID: PMC5481282): 1035-1048https://doi.org/10.2147/PPA.S134865
- Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.Patient Prefer Adherence. 2017; 11 (PMID: 28670113; PMCID: PMC5481282): 1035-1048https://doi.org/10.2147/PPA.S134865
- Updated Incidence of Natalizumab Associated Progressive Multifocal Leukoencephalopathy (PML) and its relationship with natalizumab exposure overTime.in: Presented at: 2020 American Academy of Neurology (AAN) Annual Meeting, Toronto, Canada2020 (April 25th May 1st)
- MSBase study group. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.Lancet Neurol. 2020; 19: 307-316
- Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.Lancet Neurol. 2017; 16: 925-933https://doi.org/10.1016/S1474-4422(17)30282-X)
- Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers.Neurol. Ther. 2015; 4: 147-157
- Efficacy and safety of rituximab in multiple sclerosis: experience from a developing country.Mult. Scler. Relat. Disord. 2020; 43 (Epub 2020 May 24. PMID: 32485634)102210https://doi.org/10.1016/j.msard.2020.102210
- A controlled trial of natalizumab for relapsing multiple sclerosis.N. Engl. J. Med. 2003; 348: 15-23
- Low-dose rituximab should be used for treating MS in resource-limited settings: yes.Mult. Scler. 2022; (Epub ahead of print. PMID: 35437089)13524585221089890https://doi.org/10.1177/13524585221089890
- AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.N. Engl. J. Med. 2006; 354: 899-910
- Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis.Ther. Adv. Neurol. Dis. 2019; 121756286419837809https://doi.org/10.1177/1756286419837809
- Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients.Mult. Scler. Relat. Disord. 2014; 3 (DeLuca, Andrea [corrected to De Luca, Andrea]. PMID: 20298967.) (Epub 2014 Apr 13. PMID: 25877065)): 520-526https://doi.org/10.1016/j.msard.2014.04.003
- Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients.Mult. Scler. Relat. Disord. 2014; 3 (Epub 2014 Apr 13. PMID: 25877065): 520-526https://doi.org/10.1016/j.msard.2014.04.003